MX2021014534A - Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos. - Google Patents

Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos.

Info

Publication number
MX2021014534A
MX2021014534A MX2021014534A MX2021014534A MX2021014534A MX 2021014534 A MX2021014534 A MX 2021014534A MX 2021014534 A MX2021014534 A MX 2021014534A MX 2021014534 A MX2021014534 A MX 2021014534A MX 2021014534 A MX2021014534 A MX 2021014534A
Authority
MX
Mexico
Prior art keywords
region
engineering
drive
hinge region
button
Prior art date
Application number
MX2021014534A
Other languages
English (en)
Spanish (es)
Inventor
Zhulun Wang
Fernando Garces
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2021014534A publication Critical patent/MX2021014534A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2021014534A 2019-05-30 2020-05-29 Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos. MX2021014534A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962854907P 2019-05-30 2019-05-30
PCT/US2020/035196 WO2020243477A2 (en) 2019-05-30 2020-05-29 Engineering the hinge region to drive antibody dimerization

Publications (1)

Publication Number Publication Date
MX2021014534A true MX2021014534A (es) 2022-02-11

Family

ID=72234906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014534A MX2021014534A (es) 2019-05-30 2020-05-29 Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos.

Country Status (12)

Country Link
US (1) US20220235148A1 (enExample)
EP (1) EP3976643A2 (enExample)
JP (2) JP7500619B2 (enExample)
KR (1) KR20220016139A (enExample)
CN (2) CN114174344B (enExample)
AU (1) AU2020283890A1 (enExample)
CA (1) CA3141690A1 (enExample)
EA (1) EA202193322A1 (enExample)
MX (1) MX2021014534A (enExample)
SG (1) SG11202112926YA (enExample)
TW (2) TW202525844A (enExample)
WO (1) WO2020243477A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
WO2022223016A1 (en) * 2021-04-23 2022-10-27 Chimagen Biosciences, Ltd Heterodimeric antibodies and antigen-binding fragment thereof
KR20250051674A (ko) * 2022-07-22 2025-04-17 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 다중특이적 항체의 중쇄 및 경쇄의 상동성 페어링을 촉진하는 돌연변이체
CN115232214A (zh) * 2022-08-16 2022-10-25 广州市拜沃思生物科技有限公司 一种双特异性抗体及其制备方法和应用
TW202506725A (zh) * 2023-04-07 2025-02-16 美商麥迪紐有限責任公司 三特異性工程化抗體
WO2024242490A1 (ko) * 2023-05-24 2024-11-28 삼성바이오로직스 주식회사 Ch3 도메인 변이체 또는 이를 포함하는 이중 특이적 항체
WO2025167974A1 (zh) * 2024-02-07 2025-08-14 上海齐鲁制药研究中心有限公司 多特异性抗体或抗原结合片段

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2003025020A1 (en) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Method of constructing camel antibody library
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
IN2009DN05758A (enExample) 2007-03-12 2015-07-24 Esbatech Ag
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
PL2158315T3 (pl) 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
CN102369215B (zh) * 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (en) * 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP4011913A1 (en) * 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
SI2771364T1 (sl) 2011-10-27 2019-10-30 Genmab As Produkcija heterodimernih proteinov
CA2859755C (en) * 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
RU2655439C2 (ru) * 2013-05-31 2018-05-28 Займворкс Инк. Гетеромультимеры с уменьшенной или подавленной эффекторной функцией
JP6509852B2 (ja) * 2013-07-31 2019-05-08 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）の構築物
WO2015173756A2 (en) * 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
AU2020283890A1 (en) 2021-12-16
TW202110877A (zh) 2021-03-16
TW202525844A (zh) 2025-07-01
US20220235148A1 (en) 2022-07-28
CA3141690A1 (en) 2020-12-03
JP2024113040A (ja) 2024-08-21
CN114174344B (zh) 2024-11-22
KR20220016139A (ko) 2022-02-08
WO2020243477A3 (en) 2021-01-07
EA202193322A1 (ru) 2022-03-10
CN114174344A (zh) 2022-03-11
TWI879770B (zh) 2025-04-11
EP3976643A2 (en) 2022-04-06
WO2020243477A2 (en) 2020-12-03
JP2022534901A (ja) 2022-08-04
JP7500619B2 (ja) 2024-06-17
SG11202112926YA (en) 2021-12-30
CN119431599A (zh) 2025-02-14

Similar Documents

Publication Publication Date Title
MX2021014534A (es) Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos.
PE20200717A1 (es) Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
AR117658A2 (es) Anticuerpos anti-fap y métodos de uso
AR106466A1 (es) Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih
PE20170585A1 (es) Moleculas de union a antigeno biespecificas activadoras de celulas t
PE20170071A1 (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas
CY1124644T1 (el) Βελτιστοποιηση διαλυτοτητας των ανοσοσυνδετικων μοριων
CR20180484A (es) Moléculas de unón b7-h3 novedosas, conjugados anticuerpos-fármaco de los mismos y métodos de uso de los mismos
ECSP16070447A (es) Moleculas de anticuerpo para tim-3 y sus usos
EA202091217A1 (ru) Конъюгат аналога тубулизина с разветвленными линкерами
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
UY37127A (es) Moléculas de unión a ror1, y métodos de uso de las mismas
AR091218A1 (es) Agente terapeutico o agente profilactico para los trastornos cognitivos
MX369276B (es) Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
CY1125181T1 (el) Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων
PE20190737A1 (es) Anticuerpos anti-cd27
BR112018007152A2 (pt) construtos de polipeptídeo de ligação a antígeno compreendendo cadeias leves kappa e lambda e usos dos mesmos
PE20250415A1 (es) Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PE20141212A1 (es) Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase 1
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
CL2017003273A1 (es) Inmunoglobulinas conjugadas en cys80
PE20231080A1 (es) Anticuerpos que se unen a cd3 y cd19
MX2024001067A (es) Composicion farmaceutica y uso.